新德里金属β-内酰胺酶产生菌引起的血流感染在区域暴发期间的临床特征及转归
Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing During a Regional Outbreak.
作者信息
Falcone Marco, Tiseo Giusy, Antonelli Alberto, Giordano Cesira, Di Pilato Vincenzo, Bertolucci Pietro, Parisio Eva Maria, Leonildi Alessandro, Aiezza Noemi, Baccani Ilaria, Tagliaferri Enrico, Righi Lorenzo, Forni Silvia, Sani Spartaco, Mechi Maria Teresa, Pieralli Filippo, Barnini Simona, Rossolini Gian Maria, Menichetti Francesco
机构信息
Infectious Disease Unit, Azienda Ospedaliera Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy.
出版信息
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011. doi: 10.1093/ofid/ofaa011. eCollection 2020 Feb.
Abstract
Limited data about New Delhi metallo-β-lactamase (NDM) bacteremia are available. Blood isolates from 40 patients with NDM bacteremia were studied for antibiotic susceptibility and whole-genomic sequencing. NDM bacteremia has high 30-day mortality. In most cases, aztreonam-avibactam is active in vitro. Ceftazidime-avibactam plus aztreonam may represent a feasible therapeutic option.
摘要
关于新德里金属β-内酰胺酶（NDM）菌血症的资料有限。对40例NDM菌血症患者的血液分离株进行了抗生素敏感性和全基因组测序研究。NDM菌血症的30天死亡率很高。在大多数情况下，氨曲南-阿维巴坦在体外具有活性。头孢他啶-阿维巴坦加氨曲南可能是一种可行的治疗选择。
相似文献
1
Clinical Features and Outcomes of Bloodstream Infections Caused by New Delhi Metallo-β-Lactamase-Producing During a Regional Outbreak.
Open Forum Infect Dis. 2020 Jan 21;7(2):ofaa011. doi: 10.1093/ofid/ofaa011. eCollection 2020 Feb.
2
A Case of New Delhi Metallo-β-Lactamases (NDM) Citrobacter sedlakii Osteomyelitis Successfully Treated With Ceftazidime-Avibactam and Aztreonam.
Cureus. 2022 Sep 6;14(9):e28855. doi: 10.7759/cureus.28855. eCollection 2022 Sep.
3
The Revival of Aztreonam in Combination with Avibactam against Metallo-β-Lactamase-Producing Gram-Negatives: A Systematic Review of In Vitro Studies and Clinical Cases.
Antibiotics (Basel). 2021 Aug 20;10(8):1012. doi: 10.3390/antibiotics10081012.
4
Aztreonam plus Clavulanate, Tazobactam, or Avibactam for Treatment of Infections Caused by Metallo-β-Lactamase-Producing Gram-Negative Bacteria.
Antimicrob Agents Chemother. 2019 Apr 25;63(5). doi: 10.1128/AAC.00010-19. Print 2019 May.
5
Case report: Continuous infusions of ceftazidime-avibactam and aztreonam in combination through elastomeric infusors for 12 weeks for the treatment of bone and joint infections due to metallo-β-lactamase producing .
Front Med (Lausanne). 2023 Aug 3;10:1224922. doi: 10.3389/fmed.2023.1224922. eCollection 2023.
6
Activity of Ceftazidime-Avibactam and Aztreonam-Avibactam against OXA-48-Carrying Enterobacteriaceae Isolated as Part of the International Network for Optimal Resistance Monitoring (INFORM) Global Surveillance Program from 2012 to 2015.
Antimicrob Agents Chemother. 2018 Nov 26;62(12). doi: 10.1128/AAC.00592-18. Print 2018 Dec.
7
Ceftazidime-avibactam use for the treatment of OXA-48- and/or New Delhi metallo-β-lactamase-producing in cancer patients: a retrospective observational study.
Ann Saudi Med. 2023 Nov-Dec;43(6):373-379. doi: 10.5144/0256-4947.2023.373. Epub 2023 Dec 7.
8
High Rates of Nonsusceptibility to Ceftazidime-avibactam and Identification of New Delhi Metallo-β-lactamase Production in Enterobacteriaceae Bloodstream Infections at a Major Cancer Center.
Clin Infect Dis. 2016 Oct 1;63(7):954-958. doi: 10.1093/cid/ciw398. Epub 2016 Jun 16.
9
In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing .
Antimicrob Resist Infect Control. 2018 Nov 21;7:142. doi: 10.1186/s13756-018-0435-9. eCollection 2018.
10
Successful treatment of ceftazidime/avibactam combined with aztreonam in the NDM-producing Klebsiella pneumoniae bloodstream and intestinal infections in a NK/T lymphoma patient with agranulocytosis during autologous hematopoietic stem cell transplantation: a case report.
Eur J Clin Microbiol Infect Dis. 2022 Nov 12:1-4. doi: 10.1007/s10096-022-04523-3.
引用本文的文献
1
AMRrounds: susceptibility to the new tetracycline-derivative eravacycline of New Delhi metallo-β-lactamase-producing complex.
JAC Antimicrob Resist. 2025 Aug 28;7(4):dlaf153. doi: 10.1093/jacamr/dlaf153. eCollection 2025 Aug.
2
Impact of multidrug resistance in cancer patients with bloodstream infections caused by Gram-negative bacilli: results from a multicentre study.
JAC Antimicrob Resist. 2025 Jul 4;7(4):dlaf116. doi: 10.1093/jacamr/dlaf116. eCollection 2025 Aug.
3
Estimated undertreatment of carbapenem-resistant Gram-negative bacterial infections in eight low-income and middle-income countries: a modelling study.
Lancet Infect Dis. 2025 Sep;25(9):1011-1019. doi: 10.1016/S1473-3099(25)00108-2. Epub 2025 Apr 30.
4
Targeted 'knock out' therapy with a combination antimicrobial regimen restores treatment options in the management of extensively drug-resistant carbapenemase-producing organisms.
J Med Microbiol. 2025 Apr;74(4). doi: 10.1099/jmm.0.002007.
5
Aerobic bacteria study, clinical spectrum, and outcome of patients with community-acquired multidrug-resistant pathogens.
J Family Med Prim Care. 2024 Nov;13(11):5052-5059. doi: 10.4103/jfmpc.jfmpc_680_24. Epub 2024 Nov 18.
6
Navigating the Current Treatment Landscape of Metallo-β-Lactamase-Producing Gram-Negative Infections: What are the Limitations?
Infect Dis Ther. 2024 Nov;13(11):2423-2447. doi: 10.1007/s40121-024-01044-8. Epub 2024 Oct 1.
7
Assessment of broth disk elution method for aztreonam in combination with ceftazidime/avibactam against isolates.
Microbiol Spectr. 2024 Oct 3;12(10):e0095324. doi: 10.1128/spectrum.00953-24. Epub 2024 Sep 3.
8
Not all carbapenem-resistant Pseudomonas aeruginosa strains are alike: tailoring antibiotic therapy based on resistance mechanisms.
Curr Opin Infect Dis. 2024 Dec 1;37(6):594-601. doi: 10.1097/QCO.0000000000001044. Epub 2024 Sep 18.
9
Synergistic Effect of Ceftazidime-Avibactam with Aztreonam on Carbapenemase-Positive MBL+, NDM+ [Letter].
Infect Drug Resist. 2024 Jul 15;17:3035-3036. doi: 10.2147/IDR.S433652. eCollection 2024.
10
Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48.
Clin Transl Sci. 2024 Jun;17(6):e13855. doi: 10.1111/cts.13855.
本文引用的文献
1
Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1.
Clin Infect Dis. 2020 Aug 14;71(4):1095-1098. doi: 10.1093/cid/ciz1155.
2
Risk factors and epidemiologic predictors of blood stream infections with New Delhi Metallo-b-lactamase (NDM-1) producing Enterobacteriaceae.
Epidemiol Infect. 2019 Jan;147:e137. doi: 10.1017/S0950268819000256.
3
NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings.
Clin Microbiol Rev. 2019 Jan 30;32(2). doi: 10.1128/CMR.00115-18. Print 2019 Mar 20.
4
Clinical outcomes after combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-48/CTX-M-15-producing Klebsiella pneumoniae infection.
J Antimicrob Chemother. 2018 Apr 1;73(4):1104-1106. doi: 10.1093/jac/dkx496.
5
Co-production of NDM-1 and OXA-232 by ST16 Klebsiella pneumoniae, Italy, 2016.
Future Microbiol. 2017 Oct;12:1119-1122. doi: 10.2217/fmb-2017-0041. Epub 2017 Sep 6.
6
New Delhi Metallo-Beta-Lactamase (NDM-1)-Producing Klebsiella Pneumoniae Isolated from a Burned Patient.
Am J Case Rep. 2017 Jul 18;18:805-809. doi: 10.12659/ajcr.903992.
7
Ceftazidime-Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae and Pseudomonas aeruginosa.
Antimicrob Agents Chemother. 2017 Aug 24;61(9). doi: 10.1128/AAC.01008-17. Print 2017 Sep.
8
Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02243-16. Print 2017 Apr.
9
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
J Antimicrob Chemother. 2016 Oct;71(10):2713-22. doi: 10.1093/jac/dkw239. Epub 2016 Jul 17.
10
Performance of the BD MAX™ instrument with Check-Direct CPE real-time PCR for the detection of carbapenemase genes from rectal swabs, in a setting with endemic dissemination of carbapenemase-producing Enterobacteriaceae.
Diagn Microbiol Infect Dis. 2016 Sep;86(1):30-4. doi: 10.1016/j.diagmicrobio.2016.06.002. Epub 2016 Jun 7.
Zotero 插件